Altimmune (ALT) Preferred Dividend Payments (2016 - 2019)
Altimmune (ALT) reported Preferred Dividend Payments of $452925.0 for Q1 2019, down 76.05% year-over-year from $1.9 million in Q1 2018, and down 41.97% on a QoQ basis from $780525.0 in Q4 2018.
Altimmune (ALT) has 4 years of Preferred Dividend Payments data on file, last reported at $452925.0 in Q1 2019.
- Quarterly Preferred Dividend Payments fell 76.05% year-over-year to $452925.0 in Q1 2019, while the trailing twelve-month figure through Dec 2019 was $452925.0 (down 86.31% YoY) and the FY2019 annual result came in at $452925.0, down 86.31% from the prior year.
- Preferred Dividend Payments declined to $452925.0 in Q1 2019 per ALT's latest filing, from $780525.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $2.8 million in Q4 2017 and bottomed at -$64139.0 in Q3 2018.
- The 4-year median for Preferred Dividend Payments is $286955.5 (2016), against an average of $750282.7.
- The widest annual swing landed in 2017, when Preferred Dividend Payments jumped 2218.34%; it then sank 103.27% in 2018.
- Tracing ALT's Preferred Dividend Payments over 4 years: stood at $120986.0 in 2016, then jumped by 2218.34% to $2.8 million in 2017, then tumbled by 72.17% to $780525.0 in 2018, then sank by 41.97% to $452925.0 in 2019.
- Per Business Quant, the three latest ALT Preferred Dividend Payments figures stand at $452925.0 (Q1 2019), $780525.0 (Q4 2018), and -$64139.0 (Q3 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 452,925.00 |
| Dec 31, 2018 | 780,525.00 |
| Sep 30, 2018 | -64,139.00 |
| Jun 30, 2018 | 700,093.00 |
| Mar 31, 2018 | 1.89 Mn |
| Dec 31, 2017 | 2.80 Mn |
| Sep 30, 2017 | 1.96 Mn |
| Jun 30, 2017 | 44,713.00 |
| Mar 31, 2017 | 118,356.00 |
| Dec 31, 2016 | 120,986.00 |
| Sep 30, 2016 | 104,548.00 |
| Jun 30, 2016 | 87,123.00 |